The EPO published patent EP3890769A1, an A1 designation application for engineered flagellin compositions useful in cancer immunotherapy. The patent covers compositions including flagellin-derived proteins and related formulations classified under multiple A61K and C07K International Patent Classification codes. The application names Genome Protection, Inc. as applicant with inventors METT, Vadim and GUDKOV, Andrei. Designated states cover 31 European and associated jurisdictions including DE, FR, GB, IT, ES, NL, BE, SE, and others.

This is a patent publication notice rather than a regulatory action requiring compliance. Pharmaceutical companies and biotechnology firms engaged in cancer immunotherapy research should review the patent claims to identify potential licensing opportunities or freedom-to-operate concerns. No immediate action is required, but intellectual property teams should monitor this application's progression through grant.